CD79b CAR-T cell therapy (Yake Biotechnology)

N/A

Report date: 2024/12/04 14:22:32

Base Information

Drug NameCD79b CAR-T cell therapy (Yake Biotechnology)
Drug Alias NameN/A
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionT lymphocyte replacementsAnti-CD79B
TargetsB-cell antigen receptor complex-associated protein beta chain
Therapy Area/IndicationsLymphoma, Non-HodgkinPrecursor Cell Lymphoblastic Leukemia-LymphomaLeukemia, Biphenotypic, Acute
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesZhejiang UniversityShanghai YaKe Biotechnology Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesShanghai YaKe Biotechnology Co LtdZhejiang University
Inactive CompaniesN/A
Active IndicationsLymphoma, Non-HodgkinPrecursor Cell Lymphoblastic Leukemia-LymphomaLeukemia, Biphenotypic, Acute
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A